Orlando, Fla.-based cataract surgery technology company LensAR closed an equity funding round with $10 million raised from 14 investors, regulatory documents show.
The fundraising effort, launched in December, was closed yesterday and use of the proceeds was not described, outside of an estimated $370,000 listed in payments to individuals listed as "executive officers, directors or promoters" of the company.
LensAR has been on a roll lately. Late last year the company launched a U.K. clinical trial of its laser-based eye surgery system for treatment of patients with presbyopia, having recently raised about $87 million to advanced global commercialization and product development.